Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business HighlightsBusiness Wire • 03/18/24
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewsWire • 03/05/24
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer DrugsSeeking Alpha • 01/25/24
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyPRNewsWire • 01/04/24
Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should KnowZacks Investment Research • 12/08/23
How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%Zacks Investment Research • 11/13/23
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingGlobeNewsWire • 11/13/23
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/08/23
What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'Zacks Investment Research • 10/09/23
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersGlobeNewsWire • 09/06/23
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/07/23